LTF and cancer: Our study demonstrates that lactoferrin differentially modulates ROS production in cancer and non-cancer cells under hypoxia: it reduces ROS in KD cells, providing potential protection, while increasing ROS in HSC2 cells, thereby amplifying radiation-induced oxidative damage (Figure 7).